6 Jun 2022 12:46
Sensyne Health plc
("Sensyne" or the "Company")
Results of General Meeting
Oxford, U.K. 6 June 2022: Sensyne Health plc (LSE:SENS) today announces that at the General Meeting held earlier today all resolutions proposed were duly passed by shareholders.
The full text of the resolutions is set out in the Notice of General Meeting in Part IV of the Circular which was sent to shareholders on 18 May 2022 (the "Circular") and is available from the Company's website at https://www.sensynehealth.com/investors/shareholder-information.
Terms used in this announcement shall be as defined in the Circular unless the context requires otherwise.
Voting on the resolutions was conducted by way of a poll and a summary of the votes received is as follows:
Res No.* | Votes For | % | Votes Against | % | Votes Total
| % of ISC | Votes Withheld*** |
1. Approval of the Sub-division of the Ordinary Shares | 94,932,989 | 94.99% | 5,002,018 | 5.01% | 99,935,007 | 60.12 | 3,060,310 |
2. Amend the Articles to include the rights of Deferred Shares | 94,832,989 | 94.99% | 5,002,018 | 5.01% | 99,835,007 | 60.06 | 3,160,310 |
3. Authority to convert Loan Notes into Ordinary Shares | 94,832,989 | 94.99% | 5,002,018 | 5.01% | 99,835,007 | 60.06 | 3,160,310 |
4. Disapplication of pre-emption rights in respect of conversion of Loan Notes into Ordinary Shares | 94,832,989 | 94.99% | 5,002,018 | 5.01% | 99,835,007 | 60.06 | 3,160,310 |
5. Authority to issue Warrants to subscribe for Ordinary Shares | 94,932,989 | 94.99% | 5,002,018 | 5.01% | 99,935,007 | 60.12 | 3,060,310 |
6. Disapplication of pre-emption rights in respect of the issue of the Warrants | 94,932,989 | 94.99% | 5,002,018 | 5.01% | 99,935,007 | 60.12 | 3,060,310 |
7. Approve the waiver granted by the Takeover Panel of the obligation under Rule 9 of the Takeover Code** | 63,035,642 | 96.20% | 2,487,708 | 3.80% | 65,523,350 | 39.42 | 3,118,462 |
8. Cancellation of the admission to trading on AIM per Rule 41 of the AIM Rules | 95,131,382 | 92.47% | 7,746,581 | 7.53% | 102,877,963 | 61.89 | 117,354 |
9. Approval of the Re-registration of the Company as a private company | 94,975,899 | 95.09% | 4,899,654 | 4.91% | 99,875,553 | 60.08 | 3,119,764 |
10. Adopt the New Articles upon the Re-registration | 94,975,899 | 95.09% | 4,899,654 | 4.91% | 99,875,553 | 60.08 | 3,119,764 |
* Resolutions numbered 1, 3, 5 and 7 were proposed and passed as ordinary resolutions and resolutions numbered 2, 4, 6, 8, 9 and 10 were proposed and passed as special resolutions.
** In accordance with the Takeover Code, the Rule 9 Waiver Resolution (resolution 7) was taken on a poll of Independent Shareholders.
***A vote withheld is not a vote in law and means the percentage of votes cast for and against excludes withheld votes.
As at 31 May 2022, the Company's issued share capital comprised of 166,464,335 Ordinary Shares, with each such Ordinary Share carrying the right to one vote. The total voting rights of the Company on the day on which shareholders had to be on the register of members in order to be eligible to vote at the General Meeting was 166,464,335.
Expected timetable for Delisting and Re-registration
The Company confirms that, as at today's date, the expected timetable for the cancellation of the admission to trading on AIM of the Company's Ordinary Shares is as follows:
Event* | Date** |
Last day of dealings on AIM in the Ordinary Shares | 17 June 2022 |
Cancellation of the admission to trading on AIM of the Ordinary Shares | 7.00 a.m. on 20 June 2022 |
Re-registration as a private limited company | On or around 4 July 2022 |
* Each of the times and dates set out in the above timetable are subject to change by the Company, in which event details of the new times and dates will be notified to London Stock Exchange plc and the Company will make an appropriate announcement to a Regulatory Information Service.
** References to times are to London time.
-ENDS-
Contact details:
Sensyne Health | ||
Alex Snow, Chief Executive Officer Richard Pye, Chief Financial Officer | +44 (0) 330 058 1845 | |
Peel Hunt LLP (Nominated Adviser and Broker) | +44 (0) 20 7418 8900 | |
Dr Christopher Golden James Steel | ||
Consilium Strategic Communications | ||
Mary-Jane Elliott Jessica Hodgson CSCSensynehealth@consilium-comms.com | +44 (0) 7780 600290 | |